News

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol

Dr Toh Tan Boon’s team is excited to share their latest clinical trial protocol in PLOS ONE, “Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol”.

Read More: Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol – PLOS ONE

view MORE related

News

2025
npj Precision Oncology – Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments
More Details >
2025
Singapore’s Balancing Act – Trade-offs of a Global City-state
More Details >
2025
Scientists use microcellular drones to deliver lung cancer-killing drugs
More Details >
get in touch and

Contact Us

For inquiries pertaining to our R&D Programs, please contact Khew Si Ying at khewsiying@nus.edu.sg

The Institute for Digital Medicine (WisDM)

  • 28 Medical Drive, #05-COR,
    Singapore 117456

© National University of Singapore. All Rights Reserved.